• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

AGER1 下调与非酒精性脂肪性肝炎和 2 型糖尿病的纤维化有关。

AGER1 downregulation associates with fibrosis in nonalcoholic steatohepatitis and type 2 diabetes.

机构信息

Gastroenterology and Hepatology, Stanford University, Stanford, and VA Palo Alto, California, USA.

Gastroenterology and Hepatology.

出版信息

J Clin Invest. 2020 Aug 3;130(8):4320-4330. doi: 10.1172/JCI133051.

DOI:10.1172/JCI133051
PMID:32657776
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7410084/
Abstract

Type 2 diabetes is clinically associated with progressive necroinflammation and fibrosis in nonalcoholic steatohepatitis (NASH). Advanced glycation end-products (AGEs) accumulate during prolonged hyperglycemia, but the mechanistic pathways that lead to accelerated liver fibrosis have not been well defined. In this study, we show that the AGEs clearance receptor AGER1 was downregulated in patients with NASH and diabetes and in our NASH models, whereas the proinflammatory receptor RAGE was induced. These findings were associated with necroinflammatory, fibrogenic, and pro-oxidant activity via the NADPH oxidase 4. Inhibition of AGEs or RAGE deletion in hepatocytes in vivo reversed these effects. We demonstrate that dysregulation of NRF2 by neddylation of cullin 3 was linked to AGER1 downregulation and that induction of NRF2 using an adeno-associated virus-mediated approach in hepatocytes in vivo reversed AGER1 downregulation, lowered the level of AGEs, and improved proinflammatory and fibrogenic responses in mice on a high AGEs diet. In patients with NASH and diabetes or insulin resistance, low AGER1 levels were associated with hepatocyte ballooning degeneration and ductular reaction. Collectively, prolonged exposure to AGEs in the liver promotes an AGER1/RAGE imbalance and consequent redox, inflammatory, and fibrogenic activity in NASH.

摘要

2 型糖尿病与非酒精性脂肪性肝炎(NASH)中的进行性坏死性炎症和纤维化密切相关。在长期高血糖的情况下,会积累晚期糖基化终产物(AGEs),但导致加速肝纤维化的机制途径尚未得到很好的定义。在这项研究中,我们表明,AGEs 清除受体AGER1 在 NASH 和糖尿病患者以及我们的 NASH 模型中下调,而促炎受体 RAGE 则被诱导。这些发现与通过 NADPH 氧化酶 4 引起的坏死性炎症、纤维化和促氧化活性有关。体内肝细胞中 AGEs 或 RAGE 缺失的抑制作用逆转了这些影响。我们证明,通过 cullin 3 的 neddylation 对 NRF2 的失调与 AGER1 的下调有关,并且通过体内使用腺相关病毒介导的方法在肝细胞中诱导 NRF2 逆转了 AGER1 的下调,降低了 AGEs 的水平,并改善了高 AGEs 饮食小鼠的促炎和纤维化反应。在 NASH 和糖尿病或胰岛素抵抗患者中,低 AGER1 水平与肝细胞气球样变性和胆管反应有关。总的来说,肝脏中长时间暴露于 AGEs 会促进 NASH 中 AGER1/RAGE 失衡以及随后的氧化还原、炎症和纤维化活性。

相似文献

1
AGER1 downregulation associates with fibrosis in nonalcoholic steatohepatitis and type 2 diabetes.AGER1 下调与非酒精性脂肪性肝炎和 2 型糖尿病的纤维化有关。
J Clin Invest. 2020 Aug 3;130(8):4320-4330. doi: 10.1172/JCI133051.
2
AGER1 deficiency-triggered ferroptosis drives fibrosis progression in nonalcoholic steatohepatitis with type 2 diabetes mellitus.AGER1缺乏引发的铁死亡驱动2型糖尿病非酒精性脂肪性肝炎的纤维化进展。
Cell Death Discov. 2023 Jun 6;9(1):178. doi: 10.1038/s41420-023-01477-z.
3
The transcription factor c-Jun/AP-1 promotes liver fibrosis during non-alcoholic steatohepatitis by regulating Osteopontin expression.转录因子 c-Jun/AP-1 通过调节骨桥蛋白表达促进非酒精性脂肪性肝炎肝纤维化。
Cell Death Differ. 2019 Sep;26(9):1688-1699. doi: 10.1038/s41418-018-0239-8. Epub 2019 Feb 18.
4
Ron Receptor Signaling Ameliorates Hepatic Fibrosis in a Diet-Induced Nonalcoholic Steatohepatitis Mouse Model.RON 受体信号转导改善饮食诱导的非酒精性脂肪性肝炎小鼠模型的肝纤维化。
J Proteome Res. 2018 Sep 7;17(9):3268-3280. doi: 10.1021/acs.jproteome.8b00379. Epub 2018 Aug 23.
5
Insulin resistance promotes Lysyl Oxidase Like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease.胰岛素抵抗促进非酒精性脂肪性肝病中赖氨酰氧化酶样蛋白2的诱导表达及纤维化积累。
Clin Sci (Lond). 2017 Jun 7;131(12):1301-1315. doi: 10.1042/CS20170175. Print 2017 Jun 1.
6
Advanced glycation endproducts induce fibrogenic activity in nonalcoholic steatohepatitis by modulating TNF-α-converting enzyme activity in mice.晚期糖基化终产物通过调节小鼠 TNF-α 转化酶活性诱导非酒精性脂肪性肝炎的纤维化活性。
Hepatology. 2013 Oct;58(4):1339-48. doi: 10.1002/hep.26491. Epub 2013 Aug 6.
7
p16 deficiency promotes nonalcoholic steatohepatitis via regulation of hepatic oxidative stress.p16基因缺失通过调节肝脏氧化应激促进非酒精性脂肪性肝炎。
Biochem Biophys Res Commun. 2017 Apr 29;486(2):264-269. doi: 10.1016/j.bbrc.2017.03.023. Epub 2017 Mar 10.
8
Genetic Nrf2 Overactivation Inhibits the Deleterious Effects Induced by Hepatocyte-Specific c-met Deletion during the Progression of NASH.遗传 Nrf2 过激活可抑制肝细胞特异性 c-met 缺失在 NASH 进展过程中引起的有害影响。
Oxid Med Cell Longev. 2017;2017:3420286. doi: 10.1155/2017/3420286. Epub 2017 Jun 6.
9
Hepatocyte TAZ/WWTR1 Promotes Inflammation and Fibrosis in Nonalcoholic Steatohepatitis.肝细胞TAZ/WWTR1促进非酒精性脂肪性肝炎中的炎症和纤维化。
Cell Metab. 2016 Dec 13;24(6):848-862. doi: 10.1016/j.cmet.2016.09.016. Epub 2016 Oct 27.
10
Myeloperoxidase-Hepatocyte-Stellate Cell Cross Talk Promotes Hepatocyte Injury and Fibrosis in Experimental Nonalcoholic Steatohepatitis.髓过氧化物酶-肝细胞-星状细胞相互作用促进实验性非酒精性脂肪性肝炎中的肝细胞损伤和纤维化
Antioxid Redox Signal. 2015 Dec 1;23(16):1255-69. doi: 10.1089/ars.2014.6108. Epub 2015 Jun 24.

引用本文的文献

1
Higher plasma dicarbonyl levels are associated with liver fibrosis in obese individuals.较高的血浆二羰基水平与肥胖个体的肝纤维化有关。
Diabetes Obes Metab. 2025 Jul 29. doi: 10.1111/dom.16643.
2
The Emerging Role of Anti-Hyperglycemic Agents for the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease.降糖药物在代谢功能障碍相关脂肪性肝病管理中的新作用
Diabetes Metab Syndr Obes. 2025 Jul 23;18:2477-2491. doi: 10.2147/DMSO.S528569. eCollection 2025.
3
Protocatechualdehyde attenuates oxidative stress in diabetic cataract via GLO1-mediated inhibition of AGE/RAGE glycosylation.原儿茶醛通过GLO1介导的AGE/RAGE糖基化抑制作用减轻糖尿病性白内障中的氧化应激。
Front Pharmacol. 2025 Jun 25;16:1586173. doi: 10.3389/fphar.2025.1586173. eCollection 2025.
4
A Comprehensive Review of Metabolic Dysfunction-Associated Steatotic Liver Disease: Its Mechanistic Development Focusing on Methylglyoxal and Counterbalancing Treatment Strategies.代谢功能障碍相关脂肪性肝病综合评述:聚焦甲基乙二醛的发病机制及平衡治疗策略
Int J Mol Sci. 2025 Mar 7;26(6):2394. doi: 10.3390/ijms26062394.
5
Thirty years of NRF2: advances and therapeutic challenges.NRF2的三十年:进展与治疗挑战
Nat Rev Drug Discov. 2025 Mar 4. doi: 10.1038/s41573-025-01145-0.
6
Pharmacotherapy of Liver Fibrosis and Hepatitis: Recent Advances.肝纤维化和肝炎的药物治疗:最新进展
Pharmaceuticals (Basel). 2024 Dec 20;17(12):1724. doi: 10.3390/ph17121724.
7
The Anti-AGEing and RAGEing Potential of Isothiocyanates.异硫氰酸盐的抗衰老和抗晚期糖基化终末产物作用潜力
Molecules. 2024 Dec 19;29(24):5986. doi: 10.3390/molecules29245986.
8
Model organisms for investigating the functional involvement of NRF2 in non-communicable diseases.用于研究NRF2在非传染性疾病中功能作用的模式生物。
Redox Biol. 2025 Feb;79:103464. doi: 10.1016/j.redox.2024.103464. Epub 2024 Dec 16.
9
New insights into SUMOylation and NEDDylation in fibrosis.关于SUMO化和NEDD化在纤维化中的新见解。
Front Pharmacol. 2024 Dec 4;15:1476699. doi: 10.3389/fphar.2024.1476699. eCollection 2024.
10
Advanced glycation end products and reactive oxygen species: uncovering the potential role of ferroptosis in diabetic complications.晚期糖基化终产物和活性氧:揭示铁死亡在糖尿病并发症中的潜在作用。
Mol Med. 2024 Sep 9;30(1):141. doi: 10.1186/s10020-024-00905-9.

本文引用的文献

1
UBE2M Is a Stress-Inducible Dual E2 for Neddylation and Ubiquitylation that Promotes Targeted Degradation of UBE2F.UBE2M 是一种应激诱导的双重 E2 酶,可促进 Neddylation 和泛素化,从而促进 UBE2F 的靶向降解。
Mol Cell. 2018 Jun 21;70(6):1008-1024.e6. doi: 10.1016/j.molcel.2018.06.002.
2
HMGB1 promotes ductular reaction and tumorigenesis in autophagy-deficient livers.高迁移率族蛋白 B1(HMGB1)促进自噬缺陷肝脏中的胆小管反应和肿瘤发生。
J Clin Invest. 2018 Jun 1;128(6):2419-2435. doi: 10.1172/JCI91814. Epub 2018 May 7.
3
HMGB1 links chronic liver injury to progenitor responses and hepatocarcinogenesis.HMGB1 将慢性肝损伤与祖细胞反应和肝癌发生联系起来。
J Clin Invest. 2018 Jun 1;128(6):2436-2451. doi: 10.1172/JCI91786. Epub 2018 May 7.
4
A potent small-molecule inhibitor of the DCN1-UBC12 interaction that selectively blocks cullin 3 neddylation.一种强效的 DCN1-UBC12 相互作用小分子抑制剂,可选择性阻断泛素样蛋白连接酶 E3 复合物 CUL3 的 neddylation。
Nat Commun. 2017 Oct 27;8(1):1150. doi: 10.1038/s41467-017-01243-7.
5
Advanced glycation end products impair NLRP3 inflammasome-mediated innate immune responses in macrophages.晚期糖基化终末产物损害巨噬细胞中NLRP3炎性小体介导的先天性免疫反应。
J Biol Chem. 2017 Dec 15;292(50):20437-20448. doi: 10.1074/jbc.M117.806307. Epub 2017 Oct 19.
6
Increased liver AGEs induce hepatic injury mediated through an OST48 pathway.肝内 AGEs 的增加通过 OST48 途径诱导肝损伤。
Sci Rep. 2017 Sep 25;7(1):12292. doi: 10.1038/s41598-017-12548-4.
7
Centrilobular ductular reaction correlates with fibrosis stage and fibrosis progression in non-alcoholic steatohepatitis.中心小叶间胆管反应与非酒精性脂肪性肝炎的纤维化分期和纤维化进展相关。
Mod Pathol. 2018 Jan;31(1):150-159. doi: 10.1038/modpathol.2017.115. Epub 2017 Sep 1.
8
Hepatocyte-specific sirtuin 6 deletion predisposes to nonalcoholic steatohepatitis by up-regulation of Bach1, an Nrf2 repressor.肝细胞特异性沉默调节蛋白6缺失通过上调Nrf2抑制因子Bach1而导致非酒精性脂肪性肝炎。
FASEB J. 2017 Sep;31(9):3999-4010. doi: 10.1096/fj.201700098RR. Epub 2017 May 23.
9
A longitudinal study of whole body, tissue, and cellular physiology in a mouse model of fibrosing NASH with high fidelity to the human condition.一项对纤维化非酒精性脂肪性肝炎小鼠模型进行的全身、组织和细胞生理学纵向研究,该模型高度逼真地模拟了人类病情。
Am J Physiol Gastrointest Liver Physiol. 2017 Jun 1;312(6):G666-G680. doi: 10.1152/ajpgi.00213.2016. Epub 2017 Feb 23.
10
Deregulated neddylation in liver fibrosis.肝纤维化中NEDDylation失调
Hepatology. 2017 Feb;65(2):694-709. doi: 10.1002/hep.28933. Epub 2016 Dec 30.